---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-018328"
form_type: "8-K"
ticker: "HIND"
cik: "0001427570"
company_name: "Vyome Holdings, Inc"
filed_at: "2023-11-09T23:59:59+00:00"
generated_at: "2026-06-08T06:25:06.475369+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# ReShape Q3 revenue down 21% to $2.2M; announces $8M cost cuts for 2024

## Summary
- Revenue $2.2M in Q3 2023, down from $2.8M in Q3 2022; nine-month revenue $6.7M, down 17%.
- Gross profit margin fell to 59.8% from 75.1% in Q3; non-GAAP adjusted EBITDA loss improved to $2.9M from $4.2M.
- Cash $1.5M at Sept 30; raised $2.8M net in Oct public offering; no debt.
- Targeting ~$8M cost reductions in 2024 including RIF, aiming >40% cut in operating expenses.
- Exclusive license deal with Biorad for Obalon in India subcontinent; FDA decision on Lap-Band 2.0 Flex expected by year-end.

## SEC filing metadata
- accession: 0001558370-23-018328
- form_type: 8-K
- ticker: HIND
- cik: 0001427570
- company_name: Vyome Holdings, Inc
- filed_at: 2023-11-09T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1427570/000155837023018328/0001558370-23-018328-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1427570/000155837023018328/rsls-20231108x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-018328
- JSON: https://secwatch.observer/filing/0001558370-23-018328.json
- Plain text: https://secwatch.observer/filing/0001558370-23-018328.txt

## Key facts
- Earnings Releases
  Vyome Holdings, Inc reported financial results for three and nine months ended September 30, 2023.
  - Period: three and nine months ended September 30, 2023
  - Result: reported results
  source text: On November 8, 2023, ReShape Lifesciences Inc. (the “Company”) issued a press release announcing its financial results for the three and nine months ended September 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1427570/000155837023018328/0001558370-23-018328-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.